Kane Biotech Inc (TSE:KNE)
:KNE
Want to see TSE:KNE full AI Analyst Report?
Top Page
Kane Biotech
(KNE)
Select Model
Select Model
Rating:44Neutral
Price Target:
C$0.03
▲(13.33% Upside)
Action:ReiteratedDate:04/28/26
Overall score is constrained primarily by very weak financial performance (persistent losses, cash burn, and negative equity). Technicals provide only modest support with slightly positive momentum but a broader downtrend, while valuation is unfavorable/unclear due to negative earnings and no dividend data.
Positive Factors
Proprietary anti-biofilm platform
A proprietary anti-biofilm technology addresses persistent clinical and industrial problems where alternatives are limited. The platform nature supports multiple end-markets (wound care, animal health, industrial) and licensing, creating durable product and revenue diversification opportunities if adoption scales.
Negative Factors
Persistent net losses
Consistent net losses and deeply negative operating results erode retained capital and limit the company's ability to fund growth internally. Without sustainable profitability, the firm remains dependent on investors or lenders, constraining strategic flexibility over months to years.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary anti-biofilm platform
A proprietary anti-biofilm technology addresses persistent clinical and industrial problems where alternatives are limited. The platform nature supports multiple end-markets (wound care, animal health, industrial) and licensing, creating durable product and revenue diversification opportunities if adoption scales.
Read all positive factors
Kane Biotech (KNE) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$6.36M
Dividend YieldN/A
Average Volume (3M)112.95K
Price to Earnings (P/E)―
Beta (1Y)0.67
Revenue GrowthN/A
EPS GrowthN/A
CountryCA
Employees32
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding181,856,570
10 Day Avg. Volume120,057
30 Day Avg. Volume112,955
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Kane Biotech Business Overview & Revenue Model
Company Description
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops pet oral care produ...
How the Company Makes Money
Kane Biotech generates revenue primarily by commercializing products and technology based on its anti-biofilm platform. Its revenue model typically includes: (1) product sales from company-branded or partner-branded formulations that incorporate i...
Kane Biotech Earnings Call Summary
Earnings Call Date:Nov 28, 2024
(Q3-2024)
| % Change Since: |
Next Earnings Date:May 21, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant revenue growth driven by new product sales and service revenue streams. Strategic partnerships, regulatory approvals, and expansion into new markets were noted as positive developments. However, increased operating expenses and a decrease in cash reserves were challenges mentioned. Overall, the positive developments notably outweigh the drawbacks.Positive Updates
Significant Increase in Product Sales
Product sales for Q3 2024 were $598,000 compared to $4,000 in Q3 2023, primarily due to the first commercial sales of revyve Antimicrobial Wound Gel to the U.S. distributor ProgenaCare.
Negative Updates
Increased Operating Expenses
Total operating expenses for Q3 2024 were $1,170,000, an increase of 18% compared to $995,000 for Q3 2023, due to higher employee compensation, consulting, travel, and investor relation expenses.
Read all updates
Q3-2024 Updates
Positive
Negative
Significant Increase in Product Sales
Product sales for Q3 2024 were $598,000 compared to $4,000 in Q3 2023, primarily due to the first commercial sales of revyve Antimicrobial Wound Gel to the U.S. distributor ProgenaCare.
Read all positive updates
Company Guidance
During Kane Biotech's Q3 2024 earnings call, the guidance highlighted several key achievements and future expectations. The company recorded its first commercial sales of revyve Antimicrobial Wound Gel, contributing to product sales of $598,000 for the quarter, compared to just $4,000 in Q3 2023. Total revenue reached $1,283,000, significantly up from $27,000 in the previous year, with a gross profit of $559,000. Operating expenses increased by 18% to $1,170,000. Despite these expenses, the net loss from continuing operations decreased by 45% to $679,000. Kane Biotech is anticipating further growth, with plans for additional distribution agreements, regulatory approvals, and the launch of new products, including DispersinB Wound Gel trials and potential enhancements to their Lumixa product. Additionally, a $3 million private placement was announced to support these initiatives.Kane Biotech Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 427.87K | 2.08M | 148.98K | 156.73K | 1.61M |
| Gross Profit | -163.38K | 872.10K | 109.47K | 1.41M | 568.44K |
| EBITDA | -2.95M | -3.71M | -3.23M | -2.95M | -4.25M |
| Net Income | -2.72M | -3.02M | -5.03M | -3.89M | -4.60M |
Balance Sheet | |||||
| Total Assets | 2.73M | 2.49M | 5.68M | 5.62M | 6.13M |
| Cash, Cash Equivalents and Short-Term Investments | 901.70K | 358.81K | 749.25K | 1.10M | 1.15M |
| Total Debt | 2.30M | 2.29M | 9.26M | 6.86M | 4.71M |
| Total Liabilities | 3.48M | 4.12M | 14.09M | 9.76M | 7.70M |
| Stockholders Equity | -746.54K | -1.63M | -10.56M | -6.52M | -3.89M |
Cash Flow | |||||
| Free Cash Flow | -3.26M | -4.14M | -3.23M | -3.13M | -2.64M |
| Operating Cash Flow | -3.26M | -4.11M | -3.22M | -3.04M | -2.29M |
| Investing Cash Flow | -53.13K | 10.27M | -116.14K | -107.55K | -373.55K |
| Financing Cash Flow | 3.85M | -7.69M | 2.98M | 3.10M | 2.81M |
Kane Biotech Technical Analysis
Negative
0.03
Price Trends
0.04
Negative
0.04
Negative
0.04
Negative
Market Momentum
>-0.01
Negative
44.48
Neutral
66.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:KNE, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.04, and below the 200-day MA of 0.04, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 44.48 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:KNE.
Kane Biotech Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$5.43M | -0.98 | -111.11% | ― | ― | 53.72% | |
48 Neutral | C$6.00M | -0.15 | 123.88% | ― | ― | 77.21% | |
44 Neutral | C$6.36M | -3.10 | ― | ― | ― | ― | |
| ― | C$1.46M | -1.60 | ― | ― | ― | 25.09% | |
42 Neutral | C$4.97M | -4.13 | -41.36% | ― | 32.90% | -106.00% |
* Healthcare Sector Average
TSE:KNE
Kane Biotech
0.04
-0.07
-65.00%
TSE:APS
Aptose Biosciences
2.38
-0.77
-24.36%
TSE:XRTX
XORTX Therapeutics Inc
3.96
-3.69
-48.23%
TSE:QPT
Quest Pharmatech
0.04
>-0.01
-22.22%
TSE:BIOV
BioVaxys Technology
0.07
-0.23
-76.59%
TSE:MOOD
Doseology Sciences
0.62
0.32
106.67%
Kane Biotech Corporate Events
Business Operations and StrategyProduct-Related Announcements
Kane Biotech Showcases revyve Data Highlighting Improved Outcomes in Chronic Wounds
Positive
Apr 16, 2026
Kane Biotech presented new clinical and mechanistic data on its revyve antimicrobial wound care products at the Symposium on Advanced Wound Care Spring conference in Charlotte, highlighting outcomes in complex, chronic non-healing wounds. Case stu...
Business Operations and StrategyProduct-Related Announcements
Kane Biotech’s revyve Wound Gel Gains Peer-Reviewed Validation for Tackling Antibiotic-Tolerant Biofilms
Positive
Mar 17, 2026
Kane Biotech announced that the peer-reviewed journal Frontiers in Antibiotics has published a study, co-authored with University of Manitoba researchers, demonstrating strong efficacy of its revyve Antimicrobial Wound Gel against antibiotic-toler...
Business Operations and StrategyProduct-Related Announcements
Kane Biotech broadens U.S. reach with federal distributor deal and new sales force
Positive
Mar 10, 2026
Kane Biotech has moved to expand its U.S. commercialization strategy by partnering with Marathon Medical, a service-disabled veteran-owned national healthcare distributor, to sell its revyve antimicrobial wound products into federal healthcare cha...
Business Operations and StrategyProduct-Related Announcements
Kane Biotech’s revyve Wound Gel Gains Peer-Reviewed Validation in International Wound Journal
Positive
Feb 20, 2026
Kane Biotech announced that its revyve antimicrobial wound gel has been featured in a peer-reviewed article in the International Wound Journal, highlighting the product’s thermo-reversible formulation, strong broad-spectrum antimicrobial and...
Business Operations and StrategyProduct-Related Announcements
Kane Biotech’s revyve Wound Gel Gains Peer-Reviewed Validation in International Wound Journal
Positive
Feb 20, 2026
Kane Biotech announced that its revyve Antimicrobial Wound Gel has been profiled in the International Wound Journal, highlighting a thermo-reversible formulation that turns from liquid to a form-fitting gel at body temperature and re-liquefies whe...
Business Operations and StrategyProduct-Related Announcements
Kane Biotech Expands U.S. Distribution for revyve Wound Care Line
Positive
Feb 19, 2026
Kane Biotech has signed non-exclusive U.S. distribution and sales agreements for its revyve Antimicrobial Wound Gel product line with Patient Care Medical in the Gulf Coast region and Life Biologics, which distributes nationally in advanced wound ...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Kane Biotech Wins FDA Clearance and Expands Quality Certification for revyve Wound Care Line
Positive
Feb 17, 2026
Kane Biotech has secured U.S. FDA 510(k) clearance for its revyve Antimicrobial Skin and Wound Cleanser, expanding its revyve wound care line aimed at treating a wide range of acute and chronic dermal lesions and addressing both wound bacteria and...
Business Operations and StrategyExecutive/Board ChangesProduct-Related Announcements
Kane Biotech Restarts North American Sales Push and Bolsters Wound Care Leadership
Positive
Feb 12, 2026
Kane Biotech has restarted commercial activities in the United States and Canada for its revyve Antimicrobial Wound Gel product line, signing non-exclusive distribution and sales agreements with Medstream Healthcare Solutions and Patient Care Medi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.